| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1150: Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer |
|
Medicine details |
|
| Medicine name | encorafenib (Braftovi®) with binimetinib (Mektovi®) |
| Formulation | 75 mg hard capsules; 15mg tablets |
| Reference number | 5083 & 10340 |
| Indication | In combination with binimetinib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation. |
| Company | Pierre Fabre Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 10/04/2026 |
| NICE guidance | |